Table 5.

Treatment-related cardiac toxicity

Adverse events	PLD	Epirubicin	p-value
Ventricular premature beat	3 (7.0%)	18 (20.9%)	0.043*
LVEF decline >10%	2 (4.7%)	7 (8.1%)	0.463

Note:

^*p < 0.05.

Abbreviations: PLD, pegylated liposomal doxorubicin; LVEF, left ventricular ejection fraction.